Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001209191-21-061973

Chief Scientific Officer sold 400 shares at $35.00 ($14,000)

  • Chief Scientific Officer acquired 400 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Hansen Gwenn Chief Scientific Officer 2021-10-27 Option exercise +400 $7.26 $2,904 14,597 D
Hansen Gwenn Chief Scientific Officer 2021-10-27 Sale −400 $35.00 $14,000 14,197 D
Derivatives
Hansen Gwenn Chief Scientific Officer 2021-10-27 Option exercise · Employee Stock Option (right to buy) −400 68,666 D
Open-market sales · 400 sh · avg $35.00 · $14,000
Loading xslF345X03/doc4.xml…